Skeletal anomalies in hyper-IgE recurrent infection syndrome (HIES, Job syndrome)*1

2004 ◽  
Vol 113 (2) ◽  
pp. S46
Author(s):  
J CHINEN
2009 ◽  
Vol 20 ◽  
pp. S40
Author(s):  
Pablo Guisado Vasco ◽  
Guadalupe Fraile Rodríguez ◽  
Santiago Arechaga Uriarte ◽  
Maria Eugenia Reguero ◽  
Federico Ferrere Gonzalez ◽  
...  

2000 ◽  
Vol 7 (3) ◽  
pp. 240-244 ◽  
Author(s):  
Timothy A. M. Chuter ◽  
Gregory C. Lukaszewicz ◽  
Linda M. Reilly ◽  
Robert K. Kerlan ◽  
Rishad Faruqi ◽  
...  

Infectio ro ◽  
2017 ◽  
Vol 3 (51) ◽  
Author(s):  
Mădălina Irina Mitran ◽  
Cristina Iulia Mitran ◽  
Mircea Tampa ◽  
Maria Isabela Sârbu ◽  
Alexandra Mihaela Popa ◽  
...  

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1208-1212
Author(s):  
Amol Madhav Deshpande ◽  
Mayuri Amol Deshpande

In last two decade world suffer with three epidemic diseases like SARS-CoV, H1N1 influenza, MERS –CoV and presently the world under a pandemic of Covid-19, out of these SARS-CoV, MERS –CoV and Covid-19 are form the same virus call as corona, which primary present on bats and transferred from animal to human, and then it transfer from human to human mostly by respiratory droplets or in the direct contact with the diseased person, these recurrent infection of corona virus is the burning issue in the word, so to avoid these recurrent infections good habitual behaviour with regular immune booster medicine should be taken which can be used in both normal and symptomatic patient for this Rasayan churna  is the best drug of choice as it is used for  rejuvenation therapy. From literally study from various recourses it is found that Rasayan churna have property anti-depressant, anti-xylotic, Immunomodulatory, Anti-diabetes, anti hypertensive, anti-inflammatory, Anti-toxic effects, Anti-arthritic, Anti-cancer effects, Anti-microbial effect, and Anti-oxidant which can be useful in preventive aspect of Covid -19 in all phase like normal individual, also can be used in asymptomatic patients and symptomatic patients, clinical study can be performed for the same to evaluate the result.


2017 ◽  
Vol 10 (1) ◽  
pp. 1
Author(s):  
Fauzia Andrini Djojosugito

Herpes simplex virus is one the most common causes of sexually transmitted diseases. This infection is common inreproductive age women and can cause severe sequealae for fetus and neonates because this virus can be transmittedto the fetus during pregnancy and the newborn. Infection of Herpes simplex can occurs as first or primary infectionand recurrent infection. Most of the case is asymptomatic. Rarely during intrauterine, the risk of transmission ofmaternal-fetal can be increased during the last trimester of pregnancy and delivery. Based on type of infection,primary or recurrent, performing a treatment with antiviral drugs or caesarean section delivery can decrease the riskof neonatal infection


2020 ◽  
pp. 219256822097822
Author(s):  
Muyi Wang ◽  
Liang Xu ◽  
Bo Yang ◽  
Changzhi Du ◽  
Zezhang Zhu ◽  
...  

Study Design: A retrospective study. Objectives: To investigate the incidence, management and outcome of delayed deep surgical site infection (SSI) after the spinal deformity surgery. Methods: This study reviewed 5044 consecutive patients who underwent spinal deformity corrective surgery and had been followed over 2 years. Delayed deep SSI were defined as infection involving fascia and muscle and occurring >3 months after the initial procedure. An attempt to retain the implant were initially made for all patients. If the infection failed to be eradicated, the implant removal should be put off until solid fusion was confirmed, usually more than 2 years after the initial surgery. Radiographic data at latest follow-up were compared versus that before implant removal. Results: With an average follow-up of 5.3 years, 56 (1.1%) patients were diagnosed as delayed deep SSI. Seven (12.5%) patients successfully retained instrumentation and there were no signs of recurrence during follow-up (average 3.4 years). The remaining patients, because of persistent or recurrent infection, underwent implant removal 2 years or beyond after the primary surgery, and solid fusion was detected in any case. However, at a minimum 1-year follow-up (average 3.9 years), an average loss of 9° in the thoracic curve and 8° in the thoracolumbar/lumbar curves was still observed. Conclusions: Delayed deep SSI was rare after spinal deformity surgery. To eradicate infection, complete removal of implant may be required in the majority of delayed SSI. Surgeons must be aware of high likelihood of deformity progression after implant removal, despite radiographic solid fusion.


2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S438-S439
Author(s):  
Tanner M Johnson ◽  
Amanda Howard ◽  
Kerry Schwarz ◽  
Lorna Allen ◽  
Misha Huang ◽  
...  

Abstract Background Recurrent Clostridioides difficile infection (rCDI) within 180 days of the index episode is associated with a 33% increase in mortality and, to-date, few treatment options exist to prevent recurrent infection. Bezlotoxumab (BEZ) is a novel therapeutic option for the prevention of rCDI, yet limited data exist regarding its effectiveness in patients at high-risk for recurrence outside of controlled trials. This study aimed to compare BEZ to a historical standard of care (SoC) cohort for the prevention of rCDI in patients at high risk for recurrence. Methods A multi-center retrospective cohort study of patients within an academic health-system with one or more risk factors for rCDI. Patients received SoC with oral vancomycin (VAN) or fidaxomicin (FDX) from January 2015 to December 2017 or BEZ, in addition to oral SoC, from September 2017 to September 2019. The primary outcome was rCDI within 90 days of completion of oral VAN or FDX. Secondary outcomes included all-cause readmission, all-cause mortality, and safety events at 90 days. Results One-hundred twenty patients received BEZ in addition to SoC (n=47) or SoC alone (n=73). Mean (SD) age was 55 (16) years, mean (SD) number of lifetime CDI was 3 (2) episodes, and 30.8% of patients had severe CDI. Six (12.8%) patients in the BEZ cohort and thirty-one (42.5%) in the SoC cohort experienced rCDI at 90 days [OR (95% CI) = 0.20 (0.07-0.53), p=< 0.01]. Incidence of all-cause mortality (2.1% vs 5.5%, p=0.67) and all-cause readmission (42.6% vs 56.2%, p=0.20) within 90 days were not statistically different between groups. Patient body weight, timing of BEZ administration, CDI severity, nor prior receipt of fecal microbiota transplantation significantly affected BEZ effectiveness. BEZ was well tolerated with one infusion-related reaction. There were no heart failure exacerbations among BEZ recipients and two exacerbations identified from control group. Conclusion In patients with at least one risk factor for rCDI, BEZ in addition to SoC was associated with lower rates of recurrent infection than SoC alone and may be a reasonable adjunct therapy in high risk patient populations. Disclosures matthew miller, PharmD, Allergan (Speaker’s Bureau)Tetraphase (Speaker’s Bureau)


Aorta ◽  
2020 ◽  
Vol 08 (03) ◽  
pp. 076-079
Author(s):  
Juan Caceres ◽  
Vikram Sood ◽  
Linda Farhat ◽  
Bo Yang

AbstractWe report an intricate aortic root replacement in a young male patient suffering from native valve infective endocarditis due to Serratia marcescens. Further complicating the total root replacement, there was an unknown infected aortic thrombus and a concomitant anomalous right coronary artery with an intramural course. As a result of our more aggressive approach, we believe that we lowered the risk of recurrent infection of the bioprosthesis of the aortic root.


Sign in / Sign up

Export Citation Format

Share Document